## **Molecular Oncology Test Request**

**T**: (03) 7503 7794 **F**: (03) 9959 8155 E: <u>genomics@lifestrandsgx.com.au</u> W: www.lifestrandsgx.com.au Building A (G.01) 18-24 Ricketts Road Mount Waverley VIC 3149



CLINICAL	HISTORY	1	SD	PATIENT STATUS AT THE TIME OF SERVICE
				Email:
Address:				Report Copy To:
Phone/Mobile:				
Medicare No:				Date:
Sex at Birth:	Male	Female	Unknown	Signature:
Date of Birth:				Hospital/Lab:
Given Name:				Provider No: Email:
Family Name:				Full Name:
PATIENT J	INFORMA	TION		REQUESTING PRACTITIONER
DATTENIT 1		TTON		DEQUESTING DRACTITIONED

CLINICAL HISTORY	SD	PATIENT STATUS AT THE TIME OF SERVICE
		A private patient in private hospital
		A private patient in a recognised hospital
		A public patient in a recognised hospital
		An outpatient in a recognised hospital

PAYMENT INSTRUCTIONS				
<b>Option 1: Bill Medicare</b> (If criteria are met)	MEDICARE ASSIGNMENT (Section 20a of the Health Insurance Act 1973). I offer to assign my right to benefits to the approved pathology practitioner who will render the requested pathology service(s) and any eligible pathologist determinable service(s) established as necessary by the practitioner.			
	Patient's Signature	Da	ite	
	Practitioner User Only (Reason patient cannot sign)		•	
Option 2: Bill DVA	DVA File Number:	Card Type:	Gold	White
Option 3: Bill Patient	I have discussed the out-of-pocket cost for requested test with patient (*)			
Option 4: Bill Institute or Other	Name:			

SAMPLE REQUIREMENTS			
Essential Items for All Tests (*)	<ul> <li>1× H&amp;E slide for each tissue block</li> </ul>		
()	<ul> <li>Copy of histopathology report</li> </ul>		
	Name of laboratory holding the tissue:		
	Tissue block ID:		
- OncoStrands Essential DNA, RNA or Combined	Tissue block (preferred) OR		
- OncoStrands DNA 68 or OncoStrands Extended	10× 5µm tumour tissue sections (>20% tumour cell percentage)		
<ul> <li>OncoStrands Comprehensive or OncoStrands HRD</li> </ul>	Tissue block (preferred) <b>OR</b>		
- OncoStrands Comprehensive + HRD	15× 5µm tumour tissue sections (>20% tumour cell percentage)		
OncoStrands Comprehensive Fusion     OncoStrands Neuro-Oncology	Ticsue block (proferred) OP		
57	Tissue block (preferred) OR		
– MGMT Methylation	15× 5µm tumour tissue sections (>30% tumour cell percentage)		
<ul> <li>MLH1 Methylation</li> </ul>	Tumour AND normal tissue blocks (preferred) OR		
	10× 5µm tumour and normal tissue sections each (>30% tumour cell percentage)		

## **TEST INFORMATION** (Full test details are available at www.lifestrandsgx.com.au) **OncoStrands Essential Combined** For detection of sequence variant in 45 genes, CNVs in 14 genes, fusions/exonic variants in 18 genes For detection of sequence variants in 45 genes and CNVs in 14 genes OncoStrands Essential DNA **OncoStrands Essential Fusion** For detection of gene fusions in 16 genes and AR-V7, EGFR vIII and MET exon 14 skipping variants A 68 gene assay for detection of BRCA1/2, TERT promoter variants and clinical trials variants OncoStrands DNA 68 OncoStrands Extended A 108 gene assay for detection of BRCA1/2 and other HRR gene variants, MSI status, clinical trials **OncoStrands Comprehensive** TSO500 assay for comprehensive profiling of mutations, CNVs, fusions, MSI and TMB OncoStrands Comprehensive HRD Illumina TSO500 plus HRD assay TruSight RNA Fusion assay for detection of fusions in 501 genes **OncoStrands Comprehensive Fusion** OncoStrands Neuro-Oncology A 100 gene assay for detection of SNVs, and CNVs in targeted genes and chromosomes MGMT Promoter Methylation MGMT promoter methylation testing for therapy with alkylating agents MLH1 Promoter Methylation MLH1 promoter methylation testing for IHC MLH1 loss

Your doctor has recommended that you use LifeStrands Genomics. You are free to choose your own pathology provider. However, if your doctor has specified a particular pathologist on clinical grounds, a Medicare rebate will only be payable if that pathologist performs the service. You should discuss this with your doctor.



## **Molecular Oncology Test Request**

**T**: (03) 7503 7794 **F**: (03) 9959 8155 E: genomics@lifestrandsgx.com.au W: www.lifestrandsgx.com.au Building A (G.01) 18-24 Ricketts Road Mount Waverley VIC 3149



## MEDICARE REBATABLE TESTS (No fee if criteria is met)

Code	Tumour Type	Medicare Item*	Test Available	Request
M01	Non-Small Cell Lung Cancer	Combined DNA and Fusion Testing (#73437)	OncoStrands Essential Combined	
M02	Non-Small Cell Lung Cancer	DNA Variants Testing (EGFR, KRAS, BRAF & MET) (#73438)	OncoStrands Essential DNA	
M03	Non-Small Cell Lung Cancer	EGFR T790M Variant Testing (#73351)	OncoStrands Essential DNA	
M04	Non-Small Cell Lung Cancer	Fusion Testing (ALK, ROS, RET & NTRK1/2/3) (#73439)	OncoStrands Essential Fusion	
M07	Colorectal Cancer	KRAS, NRAS, BRAF Variant Testing (#73338)	OncoStrands Essential DNA	
M08	Melanoma	BRAF V600 Variants Testing (#73336)	OncoStrands Essential DNA	
M09	Prostate Cancer	BRCA Variant Testing (#73303)	OncoStrands Extended	
M10	Ovarian Cancer, Fallopian Tube or Peritoneal Cancer	BRCA Variant Testing (#73301)	OncoStrands Extended	
M11	Ovarian Cancer, Fallopian Tube or Peritoneal Cancer	Homologous Recombination Deficiency (HRD), including BRCA1/2 Status Testing (#73307)	OncoStrands Comprehensive + HRD	
M12	Sarcoma	Gene Fusion Testing (#73376)	OncoStrands Comprehensive Fusion	
M13	Glioma, Glioneuronal & GBM	SNVs, and CNVs in Genes/Chromosomes (#73429)	OncoStrands Neuro-Oncology	
M14	Glioblastoma	MGMT Methylation Testing (#73373)	MGMT Methylation Test	
M15	Secretory Breast Cancer	NTRK1/2/3 Fusion Testing (#73433)	OncoStrands Essential Fusion	
M16	Diagnosis at <18 Years Old	NTRK1/2/3 Fusion Testing (#73433)	OncoStrands Essential Fusion	
M17	Secretory CA of Salivary Gland	NTRK1/2/3 Fusion Testing (#73433)	OncoStrands Essential Fusion	

\* All genes tested in each panel are reported including those genes covered by Medicare

	MEDICARE NON-REBATABLE TESTS (Fee applies)				
Code	Tumour Type	Important Biomarkers Covered^	Recommended Test	Request	
P01	All Tumours	For Comprehensive Genomic Analysis including Mutation, CNV, Fusion, MSI & TMB	OncoStrands Comprehensive		
P02	Colorectal Cancer	EGFR, KRAS, BRAF, NRAS, MLH1, PMS2, MSH2/6, ERBB2 Variants/CNV + MSI	OncoStrands Extended		
P03	Colorectal Cancer	MLH1 Promoter Methylation	MLH1 Promoter Methylation		
P04	Breast Cancer	BRCA1/2, PIK3CA, PALB2 Variants + ERBB2 CNV	OncoStrands DNA 68		
P05	Endometrial Cancer	POLE, TP53, ERBB2 CNV + MSI	OncoStrands Extended		
P06	GIST	KIT, PDGFRA Variants	OncoStrands Essential DNA		
P07	Pancreatic Cancer	BRCA1/2, BRAF, KRAS, ERBB2, PALB2 + MSI	OncoStrands Extended		
P08	Sarcoma	501 Fusion Genes + GNAS, CTNNB1 Variants	OncoStrands Comprehensive Fusion + OncoStrands DNA 68		
P09	Stomach Cancer	BRAF, RAS, ERBB2 Variants/CNV +MSI	OncoStrands Extended		
P10	Thyroid Cancer	BRAF, KRAS, NRAS, HRAS, RET Variants + RET, NTRK1/2/3 Fusions	OncoStrands Essential Combined		
P11	Cholangiocarcinoma	IDH1/2, FGFR, BRCA1/2 Variants + ERBB2 CNV + FGFR1/2/3, NTRK1/2/3 Fusions	OncoStrands DNA 68 + OncoStrands Essential Fusion		
P12	Cholangiocarcinoma	IDH1/2, FGFR, BRCA1/2 Variants + ERBB2 CNV + FGFR1/2/3, NTRK1/2/3 Fusions + MSI	OncoStrands Extended + OncoStrands Essential Fusion		
P13	Bladder Cancer	BRAF, FGFR1/2/3 Variants + FGFR2, NTRK1/2/3 Fusions	OncoStrands Essential Combined		
P14	Brain Cancer	SNVs and CNVs in tested genes and chromosomes	OncoStrands Neuro-Oncology		
P15	Brain Cancer	Fusions in 501 Genes	OncoStrands Comprehensive Fusion		
P16	Brain Cancer	Fusions in BRAF & NTRK1/2/3	OncoStrands Essential Fusion		

^ Included in each panel are genes not shown above, which are relevant for clinical trials eligibility, or may be of diagnostic/prognostic relevance.